acute promyelocytic leukaemia
Haematology · 2009–2015
3decisions
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| arsenic trioxide First-line treatment of acute promyelocytic leukaemia (APL) in combination with all-trans retinoic acid (ATRA) with or without chemotherapy, for both induction… | Nov 2015 | Recommended | none received |
| arsenic trioxide Induction and consolidation treatment of relapsed acute promyelocytic leukaemia (characterised by the presence of the t(15:17) translocation or PML/RAR-α… | Mar 2009 | Recommended with restriction | no section in document |
| arsenic trioxide Induction and consolidation treatment of relapsed acute promyelocytic leukaemia (characterised by the presence of the t(15:17) translocation or PML/RAR-α… | Mar 2009 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.